Genmab AS Cash Flow Conversion Efficiency
Genmab AS cash flow conversion efficiency. Based on the latest financial reports, Genmab AS (GMAB) has a cash flow conversion efficiency ratio of 0.051x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($300.34 Million) by net assets ($5.83 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Genmab AS (2002–2025)
Cash flow conversion efficiency of Genmab AS from 2002 to 2025. This chart illustrates how Genmab AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GMAB stock price for real-time trading data and today's change.
Genmab AS Cash Flow Conversion Ratio Explained
Genmab AS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Genmab AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genmab AS ranked by their cash flow conversion efficiency. Also see GMAB market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gold Circuit Electronics Ltd
TW:2368
|
0.144x |
|
ING Bank Śląski SA
WAR:ING
|
0.906x |
|
Beiersdorf Aktiengesellschaft
F:BEIA
|
0.019x |
|
Jiangsu Hengli Hydraulic Co Ltd
SHG:601100
|
0.020x |
|
China Jushi Co Ltd
SHG:600176
|
0.066x |
|
Pan American Silver Corp
TO:PAAS
|
0.069x |
|
Banco de Sabadell S.A
MC:SAB
|
0.018x |
|
ZTE Corp
SHE:000063
|
0.036x |
Annual Cash Flow Conversion Efficiency for Genmab AS (2002–2025)
The table below shows the annual cash flow conversion efficiency of Genmab AS from 2002 to 2025. Review Genmab AS free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.83 Billion | $1.19 Billion | 0.203x | -3.92% |
| 2024-12-31 | $36.70 Billion | $7.77 Billion | 0.212x | -9.30% |
| 2023-12-31 | $31.61 Billion | $7.38 Billion | 0.233x | +62.82% |
| 2022-12-31 | $27.28 Billion | $3.91 Billion | 0.143x | +42.85% |
| 2021-12-31 | $22.20 Billion | $2.23 Billion | 0.100x | -70.16% |
| 2020-12-31 | $19.12 Billion | $6.43 Billion | 0.336x | +256.43% |
| 2019-12-31 | $14.05 Billion | $1.33 Billion | 0.094x | -25.45% |
| 2018-12-31 | $8.01 Billion | $1.01 Billion | 0.127x | -50.02% |
| 2017-12-31 | $6.27 Billion | $1.59 Billion | 0.253x | +273.12% |
| 2016-12-31 | $4.83 Billion | $327.72 Million | 0.068x | -23.99% |
| 2015-12-31 | $3.49 Billion | $311.45 Million | 0.089x | +36.87% |
| 2014-12-31 | $2.03 Billion | $132.67 Million | 0.065x | +133.63% |
| 2013-12-31 | $659.52 Million | $-128.00 Million | -0.194x | -204.86% |
| 2012-12-31 | $383.19 Million | $70.92 Million | 0.185x | +120.59% |
| 2011-12-31 | $486.42 Million | $-437.23 Million | -0.899x | -462.02% |
| 2010-12-31 | $1.08 Billion | $268.17 Million | 0.248x | +156.50% |
| 2009-12-31 | $1.30 Billion | $-570.06 Million | -0.439x | -87.36% |
| 2008-12-31 | $2.19 Billion | $-513.33 Million | -0.235x | -233.68% |
| 2007-12-31 | $2.88 Billion | $505.90 Million | 0.175x | +174.30% |
| 2006-12-31 | $1.61 Billion | $-379.62 Million | -0.236x | -26.62% |
| 2005-12-31 | $1.12 Billion | $-208.64 Million | -0.186x | +40.10% |
| 2004-12-31 | $1.18 Billion | $-367.70 Million | -0.311x | -11.87% |
| 2003-12-31 | $1.09 Billion | $-302.36 Million | -0.278x | -26.30% |
| 2002-12-31 | $1.40 Billion | $-308.32 Million | -0.220x | -- |
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more